Organicell Regenerative Medicine, Inc.
OCEL · OTC
10/31/2024 | 10/31/2023 | 10/31/2022 | 10/31/2021 | |
|---|---|---|---|---|
| Revenue | $4,620 | $4,558 | $6,491 | $5,597 |
| % Growth | 1.4% | -29.8% | 16% | – |
| Cost of Goods Sold | $844 | $508 | $754 | $548 |
| Gross Profit | $3,776 | $4,051 | $5,737 | $5,050 |
| % Margin | 81.7% | 88.9% | 88.4% | 90.2% |
| R&D Expenses | $0 | $0 | $791 | $1,120 |
| G&A Expenses | $9,095 | $10,818 | $14,580 | $17,794 |
| SG&A Expenses | $9,095 | $9,895 | $14,580 | $17,794 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$29 | $345 | $25 |
| Operating Expenses | $9,095 | $10,818 | $14,580 | $17,794 |
| Operating Income | -$5,319 | -$6,767 | -$8,843 | -$12,744 |
| % Margin | -115.1% | -148.5% | -136.2% | -227.7% |
| Other Income/Exp. Net | $614 | -$220 | -$54 | -$12 |
| Pre-Tax Income | -$4,705 | -$6,987 | -$8,897 | -$12,757 |
| Tax Expense | $0 | $0 | $54 | $63 |
| Net Income | -$4,705 | -$6,987 | -$8,950 | -$12,820 |
| % Margin | -101.8% | -153.3% | -137.9% | -229% |
| EPS | -0.74 | -0.99 | -1.57 | -2.42 |
| % Growth | 25.3% | 36.9% | 35.1% | – |
| EPS Diluted | -0.74 | -0.99 | -1.57 | -2.42 |
| Weighted Avg Shares Out | 6,336 | 7,029 | 5,688 | 5,297 |
| Weighted Avg Shares Out Dil | 6,336 | 7,029 | 5,688 | 5,297 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $398 | $38 |
| Interest Expense | -$92 | $431 | $398 | $38 |
| Depreciation & Amortization | $0 | $486 | $677 | $78 |
| EBITDA | -$5,319 | -$6,069 | -$8,166 | -$12,666 |
| % Margin | -115.1% | -133.1% | -125.8% | -226.3% |